DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
CREATE, NCT05221580: China Research of IDEgAsp Treatment in Real-world Clinical practicE

Completed
N/A
887
RoW
Ryzodeg®
Novo Nordisk A/S
Diabetes Mellitus, Type 2
03/23
03/23
NCT04965051: Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Recruiting
N/A
40
RoW
insulin degludec/insulin aspart (IDegAsp), Ryzodeg, basal insulin plus pre-prandial insulin, Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra
Second Affiliated Hospital, School of Medicine, Zhejiang University
Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range
12/23
12/23
NCT05417841: Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

Not yet recruiting
N/A
224
RoW
Insulin Degludec and Insulin Aspart Injection, Ryzodeg®, Insulin Aspart Injection, NovoRapid®
Beijing Hospital
Type 2 Diabetes Mellitus
12/23
07/24
ChiCTR2400085570: Effectiveness of switching from premixed insulin to Insulin degludec/insulin aspart in patients with type 2 diabetes mellitus under the "in person-remote" diabetes mellitus self-management support model: a single-center retrospective real-world study

Not yet recruiting
N/A
100
 
None
Peking University First Hospital; Peking University First Hospital, self-funded
Type 2 Diabetes Mellitus
 
 

Download Options